‘Isolate for 10 days’: WHO issues new COVID-19 guidelines. see list here

The WHO reported that they have updated their guidance on ‘wearing a mask in a community setting’. covid-19 treatmentand clinical management.’

Amid the spread of new variants of COVID-19, WHO has urged everyone to continue wearing masks and take booster doses of the vaccine to prevent the spread of the virus.

Here’s a detailed look at the updated WHO guidelines

solitude period

WHO has said that if the patients of Kovid-19 are showing symptoms of the virus then they have to remain isolated for at least 10 days from the date of onset of symptoms.

Earlier it was said in the guidelines of WHO covid-19 patients People who show symptoms of COVID-19 will be discharged 10 days after the onset of symptoms, with at least 3 days of vigilance after symptoms disappear

-WHO mentions that if a Covid patient tests negative with an antigen-based rapid test, he/she can be discharged early from isolation

Asymptomatic Covid patients or individuals who have tested positive for the virus but do not experience any symptoms should be isolated for 5 days, WHO noted in its updated guidelines

Earlier the isolation period for these patients was ten days.

wearing a mask

Given the current spread of COVID-19 globally, WHO recommends the use of masks ‘irrespective of the local epidemiological situation’.

-WHO says wearing masks in public places still important for prevention of deadly virus

In its statements, WHO recommends the use of masks, regardless of the current prevalence of the local epidemiological situation COVID-19 Globally.

-WHO also says that the mask should be worn in the following situation

If someone has recently come in contact with Kovid-19

-When someone has or suspects COVID-19

When someone is at high risk of severe COVID-19

Anyone living in a crowded, closed or poorly ventilated area

treatment of covid-19

-WHO extends its strong recommendation for the use of Nimtrelvir-Ritonavir

-WHO also reviewed the evidence on two other drugs, sotrovimab and casirivimab-imdevimab, and made strong recommendations against their use to treat COVID-19.